Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 351 - 375 of 14743 in total

Iobenguane

Synthetic guanethidine derivative that locates phaeochromocytomas and neuroblastomas. The radioisotope used can either be iodine-123 for imaging or iodine-131 for destruction of tissues that metabolize noradrenaline. Iodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved...
Approved
Investigational
Matched Description: … Synthetic guanethidine derivative that locates phaeochromocytomas and neuroblastomas. …
Matched Categories: … Indicators and Reagents …

Pascopyrum smithii pollen

Pascopyrum smithii pollen is the pollen of the Pascopyrum smithii plant. Pascopyrum smithii pollen is mainly used in allergenic testing.
Approved
Matched Mixtures name: … Mixture of Twenty-Two Standardized and Non-Standardized Grasses …

Bendamustine

Bendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine...
Approved
Investigational
Matched Description: … a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and ... Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks ... It is active against both active and quiescent cells, although the exact mechanism of action is unknown …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index …

Avalglucosidase alfa

Avalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase (GAA) enzyme. GAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. In Pompe disease, the...
Approved
Investigational
Matched Description: … Sanofi Genzyme, avalglucosidase alfa is a chemically modified version of [alglucosidase alfa], where synthetic ... older with late-onset Pompe disease. ... [L35160] Late-onset Pompe disease is associated with a range of debilitating physical symptoms, such …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Tirzepatide

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclinical and clinical trials....
Approved
Investigational
Matched Description: … [A246260] Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty ... obesity or overweight with at least one weight-related condition. ... under a different brand name ZEPBOUND on November 8, 2023, for the chronic weight management in adults with …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Trofinetide

Trofinetide is a novel synthetic analog of glypromate, also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked...
Approved
Investigational
Matched Description: … Trofinetide is a novel synthetic analog of [glypromate], also known as glycine–proline–glutamate (GPE ... [A258438] Trofinetide is believed to work by reducing inflammation and apoptosis of neurons. ... ), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Ginkgo biloba

Ginkgo biloba extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of ginkgo biloba use the standardized extract of Ginkgo biloba (EGb) 761 (EGb761), which...
Approved
Investigational
Nutraceutical
Matched Description: … _Ginkgo biloba_ extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ... ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and ... _Ginkgo biloba_ is found in a number of homeopathic and over-the-counter herbal products and dietary …
Matched Mixtures name: … Bee Venom Wart And Tags Removal Treatment …
Matched Categories: … donepezil, memantine and Ginkgo folium ... Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates …

Sotalol

Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening...
Approved
Matched Description: … injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm ... [L6334] A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous …
Matched Categories: … Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index ... sotalol and thiazides ... Beta Blocking Agents and Thiazides ... sotalol and acetylsalicylic acid ... Beta Blocking Agents, Non-Selective, and Thiazides …

Pentostatin

A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
Approved
Investigational
Matched Description: … It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. …
Matched Categories: … Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index ... Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …

Pholcodine

Pholcodine formula is 3-o-morpholinoethylmorphine and it is classified as an antitussive which is defined as an opioid cough suppressant. It belongs to the opioid family of compounds and it is widely used. Pholcodine activity is the suppression of unproductive cough and it also has a mild sedative effect with little...
Approved
Illicit
Matched Description: … effect with little or no analgesic effects. ... It belongs to the opioid family of compounds and it is widely used. ... Pholcodine formula is 3-o-morpholinoethylmorphine and it is classified as an antitussive which is defined …
Matched Mixtures name: … Difflam Anti-Inflammatory Anti-Bacterial Lozenges With Cough Suppressant …
Matched Categories: … Heterocyclic Compounds with 4 or More Rings ... Cough and Cold Preparations ... Opium Alkaloids and Derivatives …

Corticorelin ovine triflutate

Corticorelin, available commercially as corticorelin ovine triflutate (tradename Acthrel), is a synthetic form of the peptide human corticotropin-releasing hormone (hCRH), a potent stimulator of adrenocorticotropic hormone (ACTH) release from the anterior pituitary. Endogenous forms hCRH are involved in the stress response and its main function is stimulation of the pituitary...
Approved
Matched Description: … with Cushing's disease. ... is diagnosed with ectopic ACTH syndrome. ... Corticorelin, available commercially as corticorelin ovine triflutate (tradename Acthrel), is a synthetic …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Bivalirudin

Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in...
Approved
Investigational
Matched Description: … Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin ... monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Naldemedine

Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of DB00704 to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and...
Approved
Investigational
Matched Description: … It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and ... Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation …
Matched Categories: … Alimentary Tract and Metabolism ... Heterocyclic Compounds with 4 or More Rings …

Amikacin

Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.[FDA label] Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A. Amikacin's unique property is that it exerts activity against more resistant gram-negative bacilli such as...
Approved
Investigational
Vet approved
Matched Description: … Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A. ... [FDA label] Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at ... lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population of patients with …
Matched Categories: … cefepime and amikacin ... Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index …

Baricitinib

Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Description: … [A248405] While baricitinib was granted emergency use as a treatment for COVID-19 in combination with ... By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... MATE 2 Substrates with a Narrow Therapeutic Index ... OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Dacomitinib

Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Description: … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Erlotinib

Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)...
Approved
Investigational
Matched Description: … polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential ... potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with ... EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index …

Capecitabine

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Approved
Investigational
Matched Description: … Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and ... enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and …
Matched Categories: … Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index ... Fluorouracil and prodrugs ... Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …

Varicella zoster vaccine (live/attenuated)

Live attenuated zoster vaccine is available as two products: Zostavax for the prevention of shingles in immunocompetent people over the age of 50, and Varivax for the prevention of chickenpox in individuals 12 months of age and older. While the two vaccines contain the same immunological components and provide protection...
Approved
Matched Description: … Decades later, when the body's immune system weakens with age, VZV is able to reactivate and descend ... Clinical trials for Shingrix have shown greater than 90% efficacy in adults aged 50 and older, with 89% ... Efficacy of Zostavax also wanes over time, with protection against shingles and PHN lasting only around …
Matched Mixtures name: … PROQUAD® ( Measles, Mumps, Rubella AND Varicella (Oka/Merck) Virus Vaccine Live, MSD) LYOPHILIZED VACCINE …

Nabilone

Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as...
Approved
Investigational
Matched Description: … It is also approved for use in treatment of anorexia and weight loss in patients with AIDS. ... Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy ... Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary …
Matched Categories: … Cannabinoids and similars ... Antiemetics and Antinauseants ... Alimentary Tract and Metabolism …

Dasatinib

Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein...
Approved
Investigational
Matched Description: … BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the ... ) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region ... pathogenesis of CML and 15-30% of ALL cases. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index …

Ruxolitinib

Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by...
Approved
Matched Description: … patients with lymphopenia. ... [A229708] Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations ... [A229938] Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Altretamine

An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.
Approved
Matched Description: … It also acts as a chemosterilant for male houseflies and other insects. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Pomalidomide

Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Approved
Matched Categories: … Antineoplastic and Immunomodulating Agents ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Tirbanibulin

Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. Actinic keratosis is a chronic condition characterized...
Approved
Investigational
Matched Description: … condition characterized by lesions, which can potentially transform into invasive squamous cell carcinoma with ... Tirbanibulin exhibits antitumour effects in vitro and in vivo [A225791] and has been investigated for ... Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. …
Displaying drugs 351 - 375 of 14743 in total